Intracoronary administration of levosimendan in patients with acute coronary syndromes and decreased left ventricular ejection fraction undergoing coronary artery bypass graft surgery

VJERA MARINOV, NENAD KARANOVIĆ, MLADEN CAREV, CRISTIJAN BULAT, DUBRAVKA KOČEN, MIHAJLO LOJPUR, ZDENKO COVIĆ, BOZENA IVANCEV, ZVONIMIR PARCINA

1 Anesthesiology Unit, Cito Clinic Split
2 Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Split
3 Department of Cardiac Surgery, University Hospital Split

Corresponding author:
Mladen Carev
Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Split
Spinciceva 1, 21000 Split, Croatia
Phone: +385 21 556 180
Fax: +385 21 556 580
E-mail: mladen.carev1@gmail.com

ABSTRACT

In cardiac surgery patients, intracoronary (IC) administration of levosimendan can provide optimal drug spread, enabling effective manifestation of favorable drug effects and avoiding potentially harmful systemic hypotension. This could be beneficial in acute coronary syndromes (ACS) with decreased left ventricular ejection fraction (LVEF). We present ten cases of IC administration of levosimendan in ACS manifested as ST segment elevation myocardial infarction, non-ST segment elevation myocardial infarction or unstable angina pectoris. All patients underwent coronary artery bypass graft (CABG) surgery, performed as an “off-pump” or “on-pump”/“off-clamp” procedure (latter one with the use of cardiopulmonary bypass on the beating heart). Levosimendan was administered as an IC bolus (125-250 μg) in each coronary artery graft (2-3 grafts). Intravenous (IV) levosimendan infusion continued (0.1-0.2 μg•kg•1•min−1) after graft placements (24-48 h), with IV infusion of norepinephrine (0.1 mg•ml−1), if needed. Cardiac function was assessed using LVEF (%)(Teicholz), thermodilution cardiac index (CI)(ml•m−2), and systemic vascular resistance (SVR)(dynes•sec•cm−5). Nonparametric Wilcoxon signed-ranks test [presented as median (MED) with interquartile range (IQR)] indicated a significant difference between preoperative vs. immediate postoperative CI, SVR, and LVEF in all cases (2.2 (1.9-2.5) vs. 3.1 (2.9-3.4) ml•m-2, 1173.0 (1062.7-1278.2) vs. 882.5 (763.5-993.0) dynes•sec•cm-5, 44.5 (36.0-46.7) vs. 53.5 (45.7-59.2) %, respectively] (P=0.005), i.e. IC administration of levosimendan was associated with prompt improvement of intraoperative hemodynamics and cardiac contractility. IC administration of levosimendan may be a promising alternative method for improving decreased cardiac function in acute cardiac ischemia, besides necessary surgical revascularization.

Key words: levosimendan, intracoronary, acute coronary syndromes, CABG surgery

INTRODUCTION

Patients with acute coronary syndrome (ACS), undergoing surgical myocardial revascularization, are susceptible to contractile myocardial dysfunction with hemodynamic compromise, often necessitating inotropic and/or mechanical circulatory support. (1,2) Consequently, perioperative preservation of heart function and the use of optimal inotropic agents are becoming strongly emphasized. (2,3) A calcium-sensitizing drug, levosimendan, has emerged as a novel inotropic agent with vasodilator properties and potent cardioprotective effects, all especially beneficial in coronary artery disease (CAD). (2,4) The perioperative use of levosimendan in cardiac surgery patients has been associated with a reduction in myocardial injury, improvement of hemodynamics and clinical outcomes, and reduction in additional inotropic and/or mechanical circulatory support. (1,4) In the majority of studies, levosimendan is usually administered as a continuous intravenous (IV) infusion over 24 h. (4) However, IV use of levosimendan could be limited by extensive systemic vasodilatation and hypotension, particularly in CAD. (5) Intracoronary (IC) administration of levosimendan was proposed as a possible strategy for effective regional myocardial drug distribution, facilitating favorable and avoiding potentially harmful drug effects. (6-9) We present 10 cases of IC administration of levosimendan in ACS with decreased left ventricular ejection fraction (LVEF), manifested as ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI) or unstable angina pectoris (AP), requiring coronary artery bypass graft (CABG) surgery.

MATERIALS AND METHODS

The study was approved by the local Ethics Committee of the University Hospital Split.

Technical aspects of IC levosimendan administration

CABG surgery was performed as an “off-pump” or “on-pump”/”off-clamp” proce-
dure, the latter with the use of cardiopulmonary bypass (CPB) on the beating heart. Levosimendan was administered as an IC bolus injected in each coronary artery graft. Levosimendan was first diluted (12.5 mg in 50 ml of 5% glucose solution, 250 μg•ml-1). Two ml of this drug solution was mixed with the patients heparinized blood in a 20 ml syringe (25 μg•ml-1). Prepared content from the syringe was forwarded to the surgery team in sterile conditions. A surgeon administered 5-10 ml (125-250 μg) in each coronary artery graft (2-3 grafts). After the completion of CABG surgery, IV infusion of levosimendan continued (0.1-0.2 μg•kg•1•min-1) to prolong drug delivery (24-48 h), with IV infusion of norepinephrine (0.1 mg•ml-1), if needed.

Patients

Our first case (45-year-old female in acute STEMI), was done unintentionally in an urgent manner, due to acute onset of myocardial stunning during weaning from CPB. Surgical revascularization started as Off-pump coronary artery bypass (OP-CAB), but after the first bypass was completed, the patient experienced sudden hemodynamic instability. An intra-aortic balloon pump (IABP) was positioned without expected improvement. Urgent CPB was initiated in order to place two additional grafts. During the very challenging process of weaning (hemodynamic compromise, several weaning attempts), we decided to administer an IC bolus of levosimendan in each coronary artery graft (in consultancy with colleagues from abroad). Soon after, the patient was successfully weaned from CPB with evident intraoperative improvement of hemodynamics and overall cardiac function. We continued with IC levosimendan administration in several subsequent acute STEMI cases with troponin I over 50 ng•ml-1 (5 cases). Additionally, as we continued, we found this method to be beneficial in more complicated cases of advanced chronic CAD manifested in acute form, as unstable AP (4 cases) or acute NSTEMI (1 case), with moderately elevated troponin I.

Perioperative evaluation of cardiac function and outcomes

Cardiac function was obtained with perioperative heart ultrasound estimation of LVEF (%) (Teichholz), thermodilution cardiac index (CI) (ml•m-2), and systemic vascular resistance (SVR) (dynes•sec•cm-5). Troponin I (ng•ml-1) was measured preoperatively and checked regularly. Time to extubation, intensive care unit (ICU) and hospital discharge were expressed in postoperative days (POD). POD 1 represented the first day following the day of surgery.

Statistical analysis

The results were analyzed using statistical program SPSS 14.0 with nonparametric Wilcoxon signed-ranks test for comparisons of preoperative vs. immediate postoperative values (or ICU discharge values for troponin I) of CI, SVR, LVEF, and troponin I variables in all patients. Data were presented as median (MED) with interquartile range (IQR). Statistical significance was set at P<0.05.

RESULTS

General characteristics, clinical findings and outcomes in each of ten patients are presented in table 1. Comparing preoperative vs. immediate postoperative CI, SVR, and LVEF in all patients (table 2), IC administration of levosimendan exerted significant improvement of intraoperative hemodynamics and cardiac contractility (P=0.005). Preoperative vs. ICU discharge troponin I decreased in all cases (P=0.005) (table 2).

DISCUSSION

In this short report, IC administration of levosimendan was associated with evident improvement in intraoperative hemodynamics and overall cardiac function. Jamali et al. have previously found that IC levosimendan administration enhances contractile function of stunned myocardi-um. (10) Several subsequent animal studies pointed to its cardioprotective and antiapoptotic effects. (6,7) In humans, IC administration of levosimendan improved systolic and diastolic cardiac function, in ischemic and non-ischemic acute heart failure, without significant systemic hypertension. (8,9) Our main reason for IC administration of levosimendan was globally hypokinetic myocardi-um with reduced overall cardiac function evident in every patient. Patients who underwent an “on pump”/off-clamp procedure were successfully weaned from CPB. In “off pump” cases, an IC bolus was first administered after the placement of the first graft, enabling hemodynamic stability and procedure continuation. In previous studies, IC levosimendan was used in variable doses, as an IC bolus or short continuous IC infusion. (7-9) An ongoing clinical trial chose a 12 μg•kg•1 dose of IC levosimendan infusion at the induction of cardioplegia (after opening of the aortic cross-clamp in aortic valve/CABG surgery). (4) Our 125-250 μg IC bolus administered in each coronary artery graft (2-3 grafts) during surgical revascularization, corresponded approximately to the 6-12 μg•kg•1 dose of IC levosimendan administered to each patient. Many questions arise regarding the right timing for IC levosimendan administration, optimal dose, category of patients that could benefit, and the relevant outcome measures. Further randomized control studies and/or more case series are needed to provide the correct answers.

In conclusion, as we used an IV infusion of levosimendan (following graft placements) and surgical revascularization, it is not possible to define the exact contribution of IC levosimendan to the final clinical outcome. However, we believe that IC administration of levosimendan may be a useful alternative method for improving decreased cardiac function in acute onset cardiac ischemia, in addition to necessary surgical revascularization.

ACKNOWLEDGEMENTS

The authors wish to thank Sladjana Malbas, bacc. med. techn., Andjela Pastar, bacc. med. techn., Anita Radan, bacc. med. techn., Jasenka Kosor, med. techn., and Marija Mamic, bacc. med. techn., for their technical and professional support.
Table 1. General characteristics, clinical findings and outcomes in patients with ACS administered IC levosimendan during CABG surgery.

<table>
<thead>
<tr>
<th>case</th>
<th>gender/age</th>
<th>diagnosis</th>
<th>surgery</th>
<th>remarks</th>
<th>levosimendan</th>
<th>cardiac function</th>
<th>troponin I</th>
<th>outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BMI</td>
<td></td>
<td></td>
<td>bolus</td>
<td>preop./postop.</td>
<td>(ng/ml-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(125-250 μg)</td>
<td></td>
<td>preop./ICU</td>
<td>hospital discharge</td>
</tr>
<tr>
<td>1</td>
<td>F/45</td>
<td>23.0</td>
<td>STEMI</td>
<td>IABP</td>
<td>HD 11 years</td>
<td>3 boluses + 0.1-0.2 μg/kg/min (48 h)</td>
<td>CI 1.9/3.0</td>
<td>50/7.044</td>
</tr>
<tr>
<td>2</td>
<td>M/68</td>
<td>27.4</td>
<td>STEMI</td>
<td>IABP</td>
<td>previous 1 MI, AH</td>
<td>3 boluses + 0.1-0.2 μg/kg/min (36 h)</td>
<td>CI 2.6/3.3</td>
<td>&gt;50/19.442</td>
</tr>
<tr>
<td>3</td>
<td>F/44</td>
<td>34.2</td>
<td>STEMI</td>
<td>IABP</td>
<td>AH, CRRT 2 days, intrapleural hemorrhage</td>
<td>3 boluses + 0.15-0.2 μg/kg/min (24 h)</td>
<td>CI 2.7/3.8</td>
<td>&gt;50/15.134</td>
</tr>
<tr>
<td>4</td>
<td>F/70</td>
<td>29.3</td>
<td>STEMI</td>
<td>AH</td>
<td>3 boluses + 0.1-0.15 μg/kg/min (24 h)</td>
<td>CI 2.4/2.9</td>
<td>&gt;50/22.864</td>
<td>extubation - POD 1 ICU discharge - POD 2 hospital discharge - POD 7</td>
</tr>
<tr>
<td>5</td>
<td>F/57</td>
<td>24.9</td>
<td>STEMI</td>
<td>AH, DM, IABP on POD 1</td>
<td>3 boluses + 0.1-0.15 μg/kg/min (48 h)</td>
<td>CI 2.3/2.9</td>
<td>&gt;50/20.416</td>
<td>extubation - POD 2 ICU discharge - POD 5 hospital discharge - POD 11</td>
</tr>
<tr>
<td>6</td>
<td>M/69</td>
<td>29.4</td>
<td>NSTEMI</td>
<td>CABG x 2</td>
<td>previous 2 MI, CABG x 4, postoperative delirium</td>
<td>2 boluses + 0.1-0.15 μg/kg/min for 48 h</td>
<td>CI 2.7/3.2</td>
<td>0.878/0.212</td>
</tr>
<tr>
<td>7</td>
<td>M/63</td>
<td>25.1</td>
<td>unstable AP</td>
<td>OPCAB x 3</td>
<td>recent NSTEMI, 3 boluses + 0.1-0.15 μg/kg/min (24 h)</td>
<td>CI 1.9/3.5</td>
<td>1.180/0.793</td>
<td>extubation - POD 1 ICU discharge - POD 2 hospital discharge - POD 7</td>
</tr>
<tr>
<td>8</td>
<td>M/70</td>
<td>25.5</td>
<td>unstable AP</td>
<td>OPCAB x 3</td>
<td>AH, DM, COPB</td>
<td>3 boluses + 0.1-0.15 μg/kg/min (36 h)</td>
<td>CI 2.2/3.1</td>
<td>1.403/0.644</td>
</tr>
<tr>
<td>9</td>
<td>M/80</td>
<td>25.4</td>
<td>unstable AP</td>
<td>OPCAB x 2</td>
<td>AH, DM, COPB 2 boluses + 0.1-0.2 μg/kg/min (24 h)</td>
<td>CI 2.0/2.4</td>
<td>3.081/0.626</td>
<td>extubation - POD 1 ICU discharge - POD 8 hospital discharge - POD 20</td>
</tr>
<tr>
<td>10</td>
<td>F/66</td>
<td>25.2</td>
<td>unstable AP</td>
<td>CABG x 2</td>
<td>AH, hypothyroidism</td>
<td>2 boluses + 0.1-0.2 μg/kg/min (24 h)</td>
<td>CI 1.6/3.4</td>
<td>1.691/0.426</td>
</tr>
</tbody>
</table>

ACC/ACE/ACI, common/external/internal carotid artery; ACS, acute coronary syndromes; AF, atrial fibrillation; AH, arterial hypertension; AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass grafting (“on-pump” type of surgery); CI, cardiac index (ml•m⁻²); COPB, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; DM, diabetes mellitus; F, female; HD, hemodialysis; IABP, intra-aortic balloon pump; IC, intracoronary; ICU, intensive care unit; LVEF, left ventricular ejection fraction; M, male; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; OPCAB, “off-pump” coronary artery bypass (type of surgery); POD, postoperative day; STEMI, ST segment elevation myocardial infarction; SVR, systemic vascular resistance (dynes•sec•cm⁻⁻⁵); TEA, thrombendarterectomy.
REFERENCES


Table 2. Preoperative vs. immediate postoperative values (or ICU discharge values for troponin I) of CI, SVR, LVEF, and troponin I variables in all patients (i.e. before and after IC administration of levosimendan).

<table>
<thead>
<tr>
<th>variables</th>
<th>preoperative MED (IQR)</th>
<th>postoperative MED (IQR)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI (ml•m⁻²)</td>
<td>2.2 (1.9-2.5)</td>
<td>3.1 (2.9-3.4)</td>
<td>0.005</td>
</tr>
<tr>
<td>SVR (dynes•sec•cm⁻⁵)</td>
<td>1173.0 (1062.7-1278.2)</td>
<td>882.5 (763.5-993.0)</td>
<td>0.005</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>44.5 (36.0-46.7)</td>
<td>53.5 (45.7-59.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>troponin I (ng•ml⁻¹)</td>
<td>26.54 (1.48-50)</td>
<td>3.92 (0.63-18.37)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

CI, cardiac index; IQR, interquartile range; LVEF, left ventricular ejection fraction; MED, median; SVR, systemic vascular resistance.

* P – value derived from Wilcoxon signed-ranks test; values presented as MED (IQR).